secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-031273
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed
--------------------------------------------------------------------------------

- Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.
- Cash, cash equivalents, and investments $809.3M at March 31, 2026; plus $315M Astellas upfront and equity in Q2.
- Phase 2 SOLSTICE: 77% (24/31) HDV RNA undetectable at Week 72, rising to 88% (21/24) at Week 96.
- Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2/3 in Q1 2027.
- Completed $172.5M public offering; closed Astellas collaboration for VIR-5500; first patient dosed in Phase 1 expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/0001628280-26-031273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/vir-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer